Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.

ABSTRACT: Inadequate T cell activation has severely limited the success of T cell engager (TCE) therapy, especially in solid tumors. Enhancing T cell activity while maintaining the tumor specificity of TCEs is the key to improving their clinical efficacy. However, currently, there needs to be more effective strategies in clinical practice. Here, we design novel superantigen-fused TCEs that display robust tumor antigen-mediated T cell activation effects. These innovative drugs are not only armed with the powerful T cell activation ability of superantigens but also retain the dependence of TCEs on tumor antigens, realizing the ingenious combination of the advantages of two existing drugs. Superantigen-fused TCEs have been preliminarily proven to have good (>30-fold more potent) and specific (>25-fold

SUBMITTER: Zhao WB 

PROVIDER: S-EPMC10861957 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature